Gene Therapy Market Players:
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Biogen Inc.
- Gilead Sciences, Inc.
- Bristol–Myers Squibb
- Alnylam Pharmaceuticals, Inc.
- Sarepta Therapeutics, Inc.
- Orchard Therapeutics Limited
- Celgene Corporation
- Spark Therapeutics, Inc.
- Sibino GeneTech Co., Ltd.
The introduction of new medicines, technologically sophisticated product launches, regulatory approvals, acquisitions, and joint ventures with other businesses are the activities of major players in the global market. These tactics are probably going to encourage the worldwide market's expansion.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of gene therapy is evaluated at USD 9.77 billion.
The global gene therapy market size was worth over USD 8.32 billion in 2025 and is poised to witness a CAGR of over 19.4%, crossing USD 49 billion revenue by 2035.
The North America gene therapy market is anticipated to capture 37% share by 2035, driven by the presence of sophisticated infrastructure and availability of cutting-edge technologies.
Key players in the market include Novartis AG, Biogen Inc., Gilead Sciences, Inc., Bristol–Myers Squibb, Alnylam Pharmaceuticals, Sarepta Therapeutics, Orchard Therapeutics, Celgene Corporation.
